ViewRay has set terms for its IPO, planning to offer 4 million shares in a price range between $12 and $14. If shares price at the midpoint of that range, the company will raise $52 million. Set to list on the NASDAQ under the symbol VRAY, ViewRay is a medical device company that is developing a simultaneous MRI-guided adaptive radiation therapy technology for the treatment of cancer. It last raised funding in a $15 million investment that generated a valuation of $210 million earlier this month. Backers include Aisling Capital and OrbiMed Advisors, both of which hold a 22.8% pre-IPO stake.